Cost-Effectiveness of α 2 Agonists for Intravenous Sedation in Patients With Critical Illness
JAMA Network Open · 2025
DOI: 10.1001/jamanetworkopen.2025.17533 ↗Kurz gefasst
Fachartikel in der Zeitschrift JAMA Network Open, 2025. Verfasst von Stephen Morris und 5 weiteren Autor:innen. Beteiligte Einrichtung: Primary Care Unit, Department of Public Health and Primary Care, University of Cambridge, Cambridge, United Kingdom. Hauptthemen laut MEDLINE: Critical Illness, Dexmedetomidine, Clonidine, Propofol. Die Arbeit wurde bisher 5-mal zitiert (Crossref) und nennt 27 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar.
Abstract (Originalsprache)
Importance Propofol and the α 2 agonists dexmedetomidine and clonidine are used for sedation in patients with critical illness receiving mechanical ventilation. Evidence about the cost-effectiveness of intravenous (IV) sedation with these medications is lacking.
Objective
To investigate the cost-effectiveness of dexmedetomidine-, clonidine-, and propofol-based IV sedation in patients with critical illness receiving mechanical ventilation. Design, Setting, and Participants This economic evaluation used within-trial cost-utility analysis with a 6-month time horizon comparing dexmedetomidine-, clonidine-, and propofol-based IV sedation from a UK National Health Service and Personal Social Services perspective, with individual-level data collected from the Alpha 2 Agonists for Sedation to Produce Better Outcomes From Critical Illness (A2B) trial. Adults with critical illness receiving mechanical ventilation, with an anticipated total requirement for mechanical ventilation of at least 2 days, from 41 intensive care units in the UK were included. Recruitment ran from December 2018 through October 2023; the last date of follow-up was December 10, 2023.
Interventions
Dexmedetomidine, clonidine, or propofol IV sedation. Patients receiving α 2 agonists were permitted to receive supplemental propofol to achieve the target sedation score if required. Main Outcomes and Measures Incremental costs and quality-adjusted life years (QALYs) gained between dexmedetomidine-based vs propofol-based and clonidine-based vs propofol-based IV sedation were assessed. Mean net monetary benefits with each medication were assessed.
Results
Among 1404 adults with critical illness receiving mechanical ventilation (mean [SD] age, 59.2 [14.9] years; 901 male [64.2%]), the mean (SD) Acute Physiology and Chronic Health Evaluation (APACHE) II score was 20.3 (8.2). The incremental cost for dexmedetomidine vs propofol was $1273 (95% CI, −$5000 to $7545), and for clonidine vs propofol, it was −$1328 (−$7114 to $4459). For dexmedetomidine vs propofol, there were 0.0008 QALYs (95% CI, −0.0198 to 0.0214 QALYs) gained, and for clonidine vs propofol, there were −0.0019 QALYs (95% CI, −0.0221 to 0.0181 QALYs) gained. Mean net monetary benefits for dexmedetomidine, clonidine, and propofol were −$53 278 (95% CI, −$58 063 to −$48 493), −$50 882 (95% CI, −$55 003 to −$46 762), and −$52 036 (95% CI, −$56 230 to −$47 834), respectively, at a maximum willingness to pay for a QALY of $16 250. Conclusions and Relevance In this study, dexmedetomidine-, clonidine-, and propofol-based IV sedation in patients with critical illness receiving mechanical ventilation had similar costs and QALYs. These findings suggest that economic considerations should not affect which sedative these patients receive.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Primary Care Unit, Department of Public Health and Primary Care, University of Cambridge, Cambridge, United Kingdom.
- Usher Institute, The University of Edinburgh, Edinburgh, United Kingdom.
- National Institute of Health and Social Care Research, Biomedical Research Centre, Southampton, Perioperative and Critical Care theme, University of Southampton, Southampton, United Kingdom.
Zitieren
APA
Morris, S., Lone, N. I., McKenzie, C. A., Weir, C. J., Walsh, T. S., & A2B trial investigators (2025). Cost-Effectiveness of α 2 Agonists for Intravenous Sedation in Patients With Critical Illness. JAMA Network Open. https://doi.org/10.1001/jamanetworkopen.2025.17533
Vancouver
Morris S, Lone NI, McKenzie CA, Weir CJ, Walsh TS, A2B trial investigators. Cost-Effectiveness of α 2 Agonists for Intravenous Sedation in Patients With Critical Illness. JAMA Network Open. 2025. doi:10.1001/jamanetworkopen.2025.17533
BibTeX
@article{Morris2025,
author = {Morris, Stephen and Lone, Nazir I and McKenzie, Cathrine A and Weir, Christopher J and Walsh, Timothy S and A2B trial investigators, A2B trial investigators},
title = {Cost-Effectiveness of α 2 Agonists for Intravenous Sedation in Patients With Critical Illness},
journal = {JAMA Network Open},
year = {2025},
doi = {10.1001/jamanetworkopen.2025.17533}
}
EUVIMED